News

September 2, 2015 9:45 am
A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the...
September 2, 2015 9:45 am
Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte...
September 2, 2015 9:30 am
Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this...
August 25, 2015 10:00 am
In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of precision medicine as outlined in recent articles in Science and The New England Journal of Medicine. Although precision medicine is popular and ultimately...

Pages